Molecular Partners AG disclosed that its DLL3‑targeting Radio‑DARPin candidate MP0712 produced the first patient imaging and dosimetry data at the 8th Theranostics World Congress in Cape Town, South Africa. The data were presented in two posters and an oral session and were derived from five evaluable patients who received MP0712 labeled with the diagnostic isotope 203 Pb under a Named Patient Access Program in South Africa.
The imaging results showed robust tumor uptake and a clean biodistribution profile, with low signal in healthy organs. This favorable distribution supports the design of the planned Phase 1/2a study of the therapeutic 212 Pb‑labeled version in the United States and reinforces the company’s strategy to lead the alpha‑targeted therapy space for small‑cell lung cancer and other neuroendocrine malignancies.
Management highlighted that the dosimetry extrapolations align with the Phase 1/2a dosing plan and that the data validate the Radio‑DARPin platform’s ability to achieve strong tumor accumulation while rapidly clearing from non‑target tissues. CEO Patrick Amstutz noted that the results “reinforce our ambition to become a leader in alpha‑targeted therapies” and that initial Phase 1 safety and activity data are expected later in 2026.
Molecular Partners has been operating at a loss, reporting CHF 1.55 million in revenue and a CHF 15.08 million net loss in Q2 2024, and a CHF 4.29 million revenue with a CHF 26.41 million loss for the six months ended June 30, 2024. The company’s cash runway has been extended to 2028 through a 24% workforce reduction in June 2025, which was aimed at prioritizing key clinical assets such as MP0533 and MP0712.
The company’s broader pipeline includes MP0726 for ovarian cancer and next‑generation immune cell engagers, and it has recently terminated a partnership with Novartis, a move that has prompted analysts to scrutinize its R&D progress. Despite these headwinds, the MP0712 data provide a tangible milestone that may improve investor confidence in the company’s execution and strategic focus.
The presentation underscores the company’s progress toward bringing a novel alpha‑targeted therapy to market and signals that the platform is capable of delivering the necessary tumor‑specific uptake and dosimetry profile required for clinical advancement.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.